Paul M. Armistead

Microfabricated Instrumentation to Measure Sphingolipid Signaling in Human Acute Myeloid Leukemia

National Cancer Institute · R01

PI · $3.1M · University of Washington

Leukemia Specific Splice Isoforms as Neo-Antigens for T-Cell Immunotherapy

National Cancer Institute · R01

Contact PI · $2.3M · Univ of North Carolina Chapel Hill

CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells

National Institute of Allergy and Infectious Diseases · R42

Contact PI · $1.6M · Cell Microsystems, Inc.

Leukemia Stem Cell Antigen Discovery Using Advanced Genomic and Proteomic Methods

National Heart, Lung, and Blood Institute · K08

Contact PI · $396.3K · Univ of North Carolina Chapel Hill

Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)

Principal investigator · Terminated

UNC Lineberger Comprehensive Cancer Center

Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients

Principal investigator · Completed

UNC Lineberger Comprehensive Cancer Center

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Principal investigator · Recruiting

UNC Lineberger Comprehensive Cancer Center

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Sub-investigator · Recruiting · Phase 1

UNC Lineberger Comprehensive Cancer Center